
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical Corp is experiencing significant revenue growth, with Surgical Aesthetics revenue projected to reach between $43.0 million and $45.0 million, marking a 14% increase year-over-year at the midpoint. The company's overall full-year revenue guidance has been raised to between $50.5 million and $52.5 million, driven by strong demand trends and the successful launch of its AYON Body Contouring System. Additionally, the growing adoption of GLP-1 weight-loss drugs has contributed to increased demand for surgical-quality skin procedures, enhancing Apyx's market potential and overall financial outlook.
Bears say
Apyx Medical Corp faces challenges with its Original Equipment Manufacturing (OEM) segment, which is projected to generate approximately $7.5 million, a reduction from the previous guidance of $8.0 million due to decreased sales volumes to existing customers. The stock has been negatively impacted by an FDA warning letter issued in March 2022 and market pressures related to increased GLP-1 usage, contributing to sustained volatility in its Surgical Aesthetics segment, which typically accounts for over 80% of its revenue. Additionally, the company's cash position declined from $29.3 million at the end of the second quarter of 2025 to $25.1 million at the end of the third quarter, further reflecting financial instability amid ongoing regulatory and market challenges.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares